Amitriptyline

證據等級: L5

預測適應症: 10 個

Amitriptyline: From Major Depressive Disorder to Benign Paroxysmal Torticollis of Infancy

One-Sentence Summary

Amitriptyline is a tricyclic antidepressant (TCA) first introduced in 1961 and globally established as a treatment for major depressive disorder, neuropathic pain, and migraine prophylaxis — though it currently holds no TGA registration in Australia. The TxGNN model predicts it may have utility in Benign Paroxysmal Torticollis of Infancy (BPTI), a rare childhood condition considered a migraine equivalent, with 0 clinical trials and 0 publications directly supporting this direction — this is a computational-only prediction at this stage.

Quick Overview

Item	Content
Original Indication	No TGA-approved indication in Australia; globally used for major depressive disorder, neuropathic pain, and migraine prophylaxis
Predicted New Indication	Benign Paroxysmal Torticollis of Infancy
TxGNN Prediction Score	97.72%
Evidence Level	L5
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on widely published pharmacological literature, amitriptyline is a tricyclic antidepressant that blocks presynaptic reuptake of serotonin (5-HT) and norepinephrine (NE), with additional off-target activity at histamine H1, muscarinic M1–M4, and alpha-1 adrenergic receptors. This broad receptor profile underpins its clinical utility across depression, chronic pain syndromes, and migraine prevention.

Benign Paroxysmal Torticollis of Infancy (BPTI) is a rare early-childhood disorder characterised by recurrent, self-limiting episodes of abnormal head tilt, typically accompanied by irritability, pallor, ataxia, and vomiting. Current paediatric neurology guidelines classify BPTI as a childhood migraine equivalent — a group of episodic syndromes sharing biological features with migraine, including serotonergic dysregulation and calcitonin gene-related peptide (CGRP) involvement.

The indirect mechanistic rationale proposed by TxGNN is that amitriptyline’s proven efficacy in migraine prophylaxis (via 5-HT/NE modulation and possible mild MAO inhibition) could theoretically extend to BPTI through their shared pathophysiological overlap. However, this reasoning is speculative and entirely unvalidated in clinical or preclinical settings. The high model score (97.72%) most likely reflects indirect knowledge graph propagation through intermediate nodes — amitriptyline → migraine prophylaxis → childhood migraine equivalents → BPTI — rather than direct biological or clinical evidence.

Clinical Trial Evidence

Currently no related clinical trials registered for amitriptyline in Benign Paroxysmal Torticollis of Infancy.

Literature Evidence

Currently no related literature available for amitriptyline in Benign Paroxysmal Torticollis of Infancy.

Australia Market Information

Amitriptyline is currently not listed on the Australian Register of Therapeutic Goods (ARTG). There are no ARTG entries for this drug in Australia. Use of amitriptyline in Australian clinical practice would currently require access via the TGA Special Access Scheme (SAS) Category B or the Authorised Prescriber pathway.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: There is no clinical trial or published literature directly supporting amitriptyline for Benign Paroxysmal Torticollis of Infancy; the TxGNN prediction rests entirely on indirect computational inference through migraine-related knowledge graph pathways, with no clinical or preclinical validation in this paediatric population.

To proceed, the following is needed:

Mechanism of action data confirmed from DrugBank or equivalent authoritative source
Safety and pharmacokinetic profile for paediatric and infant use (BPTI affects children under 5 years)
Any published case series or observational data on TCAs in BPTI or closely related childhood migraine equivalents
TGA regulatory pathway assessment for a paediatric indication in Australia
Paediatric neurologist consultation and independent ethics review prior to any clinical consideration
Systematic review of migraine-equivalent treatment literature to identify whether any TCA data is available as a proxy

⚠️ Disclaimer: This report is intended for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application. All content should be evaluated by qualified healthcare professionals in accordance with applicable Australian regulatory standards.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.